You are viewing the site in preview mode
Skip to main content
|
Variables
|
Mean ± SD/N (%)
|
Disease-free survival
|
Cancer-specific survival
|
|---|
|
HR (95% CI), P value
|
HR (95% CI), P value
|
|---|
|
Postoperative capecitabine duration
|
4.65 ± 6.75
|
0.91 (0.86, 0.98), 0.014
|
0.90 (0.84, 0.97), 0.0043
|
|
0
|
143 (55.64%)
|
1.0
|
1.0
|
|
≤ 12 weeks
|
79 (30.74%)
|
0.52 (0.36, 0.98), 0.030
|
0.48 (0.24, 0.99), 0.046
|
|
≤ 24 weeks
|
35 (13.62%)
|
0.26 (0.19, 0.70), 0.007
|
0.09 (0.01, 0.67), 0.018
|
|
Gender
|
|
Male
|
161 (62.65%)
|
1.0
|
1.0
|
|
Female
|
96 (37.35%)
|
1.07 (0.58–1.68), 0.21
|
1.12 (0.60, 2.08), 0.73
|
|
Age (years)
|
75.83 ± 4.60
|
1.04 (0.73–1.44), 0.77
|
1.06 (0.99, 1.12), 0.080
|
|
≥ 70, < 75
|
114 (44.36%)
|
1.0
|
1.0
|
|
≥ 75, < 80
|
84 (32.68%)
|
1.23 (0.73–2.88), 0.079
|
1.57 (0.77, 3.19), 0.21
|
|
≥ 80
|
59 (22.96%)
|
1.42 (0.75–3.13), 0.23
|
1.79 (0.83, 3.87), 0.14
|
|
T stage
|
|
1–2
|
11 (4.28%)
|
1.0
|
1.0
|
|
3
|
211 (82.10%)
|
1.40 (0.65–5.35), 0.42
|
1.30 (0.31, 5.44), 0.71
|
|
4
|
35 (13.62%)
|
1.22 (0.92–5.57), 0.069
|
1.13 (0.23, 5.62), 0.88
|
|
N stage
|
|
0
|
128 (49.81%)
|
1.0
|
1.0
|
|
1
|
104 (40.47%)
|
1.10 (0.67–3.64), 0.45
|
1.77 (0.85, 3.67), 0.13
|
|
2
|
25 (9.73%)
|
4.04 (1.93–8.99), < 0.0001
|
5.31 (2.42, 11.64), < 0.0001
|
|
Stage
|
|
II
|
128 (49.81%)
|
1.0
|
1.0
|
|
III
|
129 (50.19%)
|
2.19 (1.13, 4.66), 0.017
|
2.45 (1.26, 4.78), 0.0083
|
|
Histological type
|
|
Common type
|
221 (85.99%)
|
1.0
|
1.0
|
|
Special type
|
36 (14.01%)
|
1.28 (0.75–2.96), 0.061
|
1.69 (0.83, 3.44), 0.15
|
|
CEA
|
|
Normal
|
163 (63.42%)
|
1.0
|
1.0
|
|
Elevated
|
94 (36.58%)
|
1.29 (0.88–2.42), 0.38
|
1.15 (0.62, 2.12), 0.66
|
|
CA199
|
|
Normal
|
209 (81.64%)
|
1.0
|
1.0
|
|
Elevated
|
47 (18.36%)
|
2.68 (1.98–3.93), 0.0075
|
2.04 (1.04, 3.98), 0.037
|
|
Charlson comorbidity index
|
|
≤ 4
|
197 (76.65%)
|
1.0
|
1.0
|
|
> 4
|
60 (23.35%)
|
1.18 (0.61–3.09), 0.87
|
1.05 (0.50, 2.19), 0.90
|
|
MMR status
|
|
dMMR
|
20 (7.78%)
|
1.0
|
1.0
|
|
pMMR
|
185 (71.98%)
|
0.79 (0.42, 1.93), 0.57
|
0.51 (0.21, 1.23), 0.1338
|
|
Unknown
|
52 (20.23%)
|
0.67 (0.29, 1.84), 0.12
|
0.63 (0.22, 1.76), 0.3769
|
- Abbreviations: HR hazard ratio; CI confidence interval; CA carcinoma antigen; CEA carcinoembryonic antigen; MMR mismatch repair; dMMR mismatch repair deficiency; pMMR proficient mismatch repair
